Does the failure of pembrolizumab in multiple myeloma clinical trials imply checkpoint inhibition is unlikely to work for patients with the disease?
While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.
Ponatinib is highly effective among patients with CML, but the optimal dose is still being determined. Current trials are evaluating an initial dose of 30 mg, with a reduction to 15 mg when a response is achieved.
Hematologic Cancers News
More Hematologic Cancers Information
Despite controversy, many studies have found no significant association between aspartame consumption and the incidence of different types of solid and hematologic malignancies.
Vitamin A supplementation likely does not reduce chemotherapy efficacy and, for many patients, is unlikely to cause harm.
Though some studies reported improvements in clinical outcomes and quality of life with vitamin C treatment, these findings have not been replicated in randomized controlled studies.
Multiple studies evaluated the role of vitamin B6 in cancer risk and its efficacy as an antitumor or anti-toxicity agent.
Additional large, well-designed studies are needed to clarify the roles of dietary nutrients in HPV infection persistence and cancer risk.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis
- Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer
- FDA Grants Priority Review to Brentuximab sBLA for Cutaneous T Cell Lymphoma
- CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective